Gastrointestinal Cancer Radiotherapy
Preoperative (neoadjuvant), definitive, and stereotactic radiotherapy for esophageal, rectal, stomach, and pancreatic cancers.
Strategic radiation to downstage tumors, preserve sphincter function, and prevent recurrence.
In rectal cancer, modern neoadjuvant chemoradiation (or Total Neoadjuvant Therapy - TNT) is designed to significantly downstage tumors prior to surgery, increasing the likelihood of sphincter-saving surgery and eliminating the need for a permanent colostomy bag.
For esophageal and gastroesophageal junction (GEJ) cancers, definitive or preoperative chemoradiation (CROSS trial protocol) provides strong local control while sparing heart and lung tissue.
For inoperable pancreatic and liver tumors, Stereotactic Body Radiotherapy (SBRT) delivers concentrated biological doses with millimeter precision to arrest localized disease progression.
Key Clinical Considerations in Your Consultation
Every recommendation is customized according to staging scans, pathology markers, and patient priorities.
Neoadjuvant chemoradiation for rectal cancer with sphincter preservation goals
Total Neoadjuvant Therapy (TNT) protocols for locally advanced rectal cancer
CROSS protocol chemoradiation for esophageal and GEJ carcinomas
Liver SBRT for hepatocellular carcinoma (HCC) and liver metastases
Stereotactic radiotherapy for locally advanced pancreatic cancer
Second opinion review of pelvic MRI and staging PET/CT scans
Discuss Gastrointestinal Cancer Radiotherapy
Bring biopsy reports, recent PET/CT or MRI scans, and operative summaries for a comprehensive consultation.